Finzati - Logo
NBIX logo

Neurocrine Biosciences, Inc.

NBIX • Biotechnology
$155.64
▼ -2.71 (-1.71%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHLY FAVORABLE PROFILEExcellentConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$16.22B
Growth
11.4%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 16.7%Positive revenue growth · 24.5%Positive free cash flow · 7.52Consistent free cash flow · 5/5Manageable debt level · 0.13
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$155.64
Change-1.71%
Shares Out104.20M
Market Cap$16.22B
Enterprise Value$16.23B
52W Range122.14 - 186.12
Beta0.39
P/E22.99
P/S4.81
P/B4.06
P/FCF18.63
EV/Sales4.81

Investment DNA

How strong this company looks for long-term investors

84
out of 100
Business Quality
Margins, moat, returns
86/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
57/100
Why this score▼
Stable or improving margins · 16.7%Positive revenue growth · 24.5%Positive free cash flow · 7.52Consistent free cash flow · 5/5Manageable debt level · 0.13Healthy liquidity · 3.39

Analyst view

Analyst sentiment and price target

NBIX
Analyst sentiment
Based on 37 analyst votes · 2026-09-04
93/100
Bullish
Bullish
32
Hold
5
Bearish
0
Price Target
2026-07-31
Low
$160.00
Mean
$197.25
Median
$197.50
High
$230.00

Company Overview

IPO: 5/23/1996
Industry: Biotechnology
P/B i: 4.06
Debt / Equity i: 0.13
Operating Margin: 21.64%
Net Margin: 16.73%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.13
Current Ratio: 3.39
Quick Ratio: 3.30
Status: Good

Insider Transactions

Recent executive and insider activity

Norwalk Leslie V
Transaction: 07/29/2026
SELL
Change
-842
Price
$139.43
Filing
07/30/2026
Type
SELL
Norwalk Leslie V
Transaction: 07/29/2026
BUY
Change
+842
Price
$139.43
Filing
07/30/2026
Type
BUY
Norwalk Leslie V
Transaction: 07/28/2026
SELL
Change
-1,250
Price
$182.01
Filing
07/30/2026
Type
SELL